NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDCapecitabine  Malignant disease and immunosuppression, Antimetabolites, 08.01.03
REDUridine Triacetate Vistogard®
(10g Oral Granules) 		Malignant disease and immunosuppression, Drugs for cytotoxic-induced side-effects, 08.01
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Capecitabine Capecitabine [Specialist Drug] Malignant Disease, Cytotoxic Responsive Malignancy, Antineoplastic Drugs Antimetabolites
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
Clinical Commissioning Urgent Policy Statement: Uridine triacetate for the treatment of patients exhibiting earlyonset severe toxicities following 5-fluorouracil or capecitabine administration (all ages)
MHRA Drug Safety Update (October 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
NICE TA191: Gastric cancer (advanced) - capecitabine
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
NICE TA263: Breast cancer with capecitabine
NICE TA61: Metastatic colorectal cancer - capecitabine and tegafur uracil
NICE TA786 Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies